UNSPSC 51281604: Arbekacin

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7V6SLI20L, chemically known as o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->6))-n-((2s)-4-amino-2-hydroxybutyryl)-2-deoxy-l-streptamine but generally known as arbekacin, which bears US NIH Compound Identifier 68682. Arbekacin most often comes in base and sulfate forms.

UNSPSC 51281604 Arbekacin is a Commodity code nominally denoting a specific antibiotic, but recent state and local opportunities tagged under this code do not reflect procurement of arbekacin itself; rather, they reflect broader emergency medical supplies, pharmaceuticals, and pharmacy benefit program services. Seminole County, Florida issued an IFB in June 2026 for naloxone and safe drug deactivation systems; the City of Tampa issued an IFB in March 2026 for medical and first aid supplies including respiratory equipment, cardiac monitoring devices, and consumables for the Fire Department Rescue Division; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities in Minnesota and Oregon. The code shows activity from state agencies, county health departments, and municipal fire departments, alongside cooperative purchasing vehicles. The Texas Health and Human Services Commission issued a Request for Information in April 2026 seeking vendor capabilities for a direct-to-manufacturer pharmacy program, signaling exploratory procurement planning rather than immediate contract awards.

Recent activity concentrates in Florida, Minnesota, Oregon, and Texas. The Seminole County naloxone and drug deactivation systems procurement (IFB 60459723LAS, response deadline July 26, 2023) involves 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries; the contract includes a two-year initial term with optional one-year renewal and an estimated value of approximately $700,000 when extrapolated from the City of Tampa's medical supplies IFB (Bid 26-P-00145, due March 13, 2026), which is sheltered for certified Small Local Business Enterprises with a 5 percent SLBE bid discount capped at $10,000. The MMCAP RFP (S1070000015802, proposals due March 26, 2026) covers generic pharmaceuticals and OTC products through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness, contract effective July 1, 2026, and a two-year initial term. The Texas RFI does not specify budget or timeline and functions as preliminary market intelligence for future formal solicitation.